{"id":"https://openalex.org/W2590591109","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","title":"Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) \u00b1 enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)","display_name":"Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) \u00b1 enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2590591109","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","mag":"2590591109"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.8037","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016064449","display_name":"Coleman K. Obasaju","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. K. Obasaju","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110302696","display_name":"Robert N. Raju","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. N. Raju","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Stinchcombe","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054058829","display_name":"Linda S. Couch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. S. Couch","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049504224","display_name":"Robert M. Jotte","orcid":"https://orcid.org/0000-0003-3920-0731","observed_orcids":["https://orcid.org/0000-0003-3920-0731"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Jotte","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082618238","display_name":"Darren M. Kocs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. M. Kocs","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023458838","display_name":"Y. Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. Wang","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000035636","display_name":"Jane L. Bromund","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Bromund","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061100035","display_name":"Joseph Treat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Treat","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. A. Socinski","raw_affiliation_strings":["Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly USA, LLC, Indianapolis, IN; US Oncology, Houston, TX; Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"8037","last_page":"8037"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.8393999934196472,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.1527000069618225,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9110000133514404},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.9399999976158142},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/enzastaurin","display_name":"enzastaurin","score":0.9779999852180481},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9980000257492065},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.8920000195503235},{"id":"https://openalex.org/keywords/stage-iiib-iv-nsclc","display_name":"stage IIIB/IV NSCLC","score":0.824999988079071},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6819999814033508},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.7009999752044678},{"id":"https://openalex.org/keywords/serine-threonine-kinase-inhibitors","display_name":"serine/threonine kinase inhibitors","score":0.828000009059906},{"id":"https://openalex.org/keywords/platinum-doublets","display_name":"platinum doublets","score":0.5799999833106995},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5070000290870667},{"id":"https://openalex.org/keywords/steroid-prophylaxis","display_name":"steroid prophylaxis","score":0.9599999785423279},{"id":"https://openalex.org/keywords/metastatic-lung-cancer","display_name":"metastatic lung cancer","score":0.5080000162124634},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.4740000069141388},{"id":"https://openalex.org/keywords/egfr-tki-resistance","display_name":"EGFR tyrosine kinase inhibitor resistance","score":0.4790000021457672}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9177436828613281},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.6742702126502991},{"id":"https://openalex.org/C2780350996","wikidata":"https://www.wikidata.org/wiki/Q420532","display_name":"Vinorelbine","level":4,"score":0.6581639051437378},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6434745788574219},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6385060548782349},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.6148240566253662},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5901126861572266},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.5867113471031189},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.5569152235984802},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5104802846908569},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.49815797805786133},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4954935312271118},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.47570452094078064},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4686291515827179},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39058026671409607},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.344354510307312},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.34338152408599854},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.21204757690429688}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.8037","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.8037","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4205274925","https://openalex.org/W2031871042","https://openalex.org/W2970478318","https://openalex.org/W2061303642","https://openalex.org/W2097268198","https://openalex.org/W2599075802","https://openalex.org/W2228607810","https://openalex.org/W2015201549","https://openalex.org/W2006813505","https://openalex.org/W2226373164"],"abstract_inverted_index":{"8037":[0],"Background:":[1],"E":[2,115,172,259],"is":[3],"a":[4,89,117,176,247],"selective,":[5],"oral":[6],"serine/threonine":[7],"kinase":[8],"inhibitor.":[9],"The":[10,54,103,194],"combination":[11],"of":[12,23,70,76,92,120,139,179,197,266,293],"PCb":[13,113,198,243,268],"has":[14],"shown":[15],"clinical":[16],"activity":[17,265],"in":[18,254,284],"two":[19],"phase":[20,27],"2":[21],"trials":[22],"advanced":[24,255],"NSCLC.":[25,258],"A":[26],"3":[28,155,166,211],"trial":[29,108],"among":[30],"pts":[31,127],"with":[32,44,58,73,88,128,171,242,246],"stage":[33,129],"IIIB/IV":[34],"NSCLC":[35],"showed":[36],"that":[37],"P":[38,59,158,218],"+":[39,49,60,84,100],"cisplatin":[40,50,85,101],"provides":[41],"similar":[42],"efficacy":[43],"better":[45],"tolerability":[46],"than":[47,252],"gemcitabine":[48],"(Scagliotti,":[51],"JCO,":[52],"2008).":[53],"toxicity":[55],"profile":[56],"observed":[57],"platinum":[61],"doublets":[62],"makes":[63],"these":[64],"regimens":[65],"attractive":[66],"for":[67,98,281],"the":[68,79,264,267,285,291,294],"integration":[69],"novel":[71],"agents":[72],"different":[74],"mechanisms":[75],"action.":[77],"In":[78],"TAX":[80],"326":[81],"trial,":[82],"D":[83,203,230],"was":[86,109,244],"associated":[87,245],"median":[90],"survival":[91,251],"11.3":[93],"mos":[94,97],"vs.":[95],"10.1":[96],"vinorelbine":[99],"(P=.04).":[102],"current":[104],"open-label":[105],"three-":[106],"arm":[107,119],"designed":[110],"to":[111,154,263,275],"assess":[112],"\u00b1":[114],"versus":[116],"control":[118],"DCb.":[121],"Methods:":[122],"Between":[123],"3/06":[124],"and":[125,143,161,206,225,272],"5/08,":[126],"IIIB":[130],"(with":[131],"pleural":[132],"effusion)":[133],"or":[134,141,182,201,256],"IV":[135],"NSCLC,":[136],"ECOG":[137],"PS":[138],"0":[140],"1,":[142],"no":[144],"prior":[145],"systemic":[146],"therapy":[147],"were":[148,151,219],"enrolled.":[149],"Pts":[150,216,228],"equally":[152],"randomized":[153],"arms:":[156],"(A)":[157],"500":[159,187],"mg/m2":[160,205],"Cb":[162,207],"AUC":[163,208],"6":[164,169,209,214],"every":[165,210],"wks":[167,212],"\u00d7":[168,213],"cycles":[170],"given":[173],"orally":[174],"as":[175],"loading":[177],"dose":[178],"1200":[180],"mg":[181,184,188],"1125":[183],"followed":[185],"by":[186],"daily":[189],"until":[190],"disease":[191],"progression;":[192],"(B)":[193],"same":[195],"regimen":[196],"without":[199],"E;":[200],"(C)":[202],"75":[204],"cycles.":[215],"receiving":[217],"administered":[220],"folic":[221],"acid,":[222],"vitamin":[223],"B12":[224],"steroid":[226,233],"prophylaxis.":[227,234],"on":[229],"also":[231],"received":[232],"Results:":[235],"See":[236],"table":[237],".":[238],"Conclusions:":[239],"First-line":[240],"treatment":[241],"significantly":[248],"longer":[249],"overall":[250],"DCb":[253,273],"metastatic":[257],"did":[260],"not":[261],"add":[262],"doublet.":[269],"PCbE,":[270],"PCb,":[271],"appeared":[274],"be":[276,288],"well":[277],"tolerated.":[278],"Complete":[279],"results":[280],"all":[282],"patients":[283],"study":[286],"will":[287],"available":[289],"at":[290],"time":[292],"meeting.":[295],"[Table:":[296,299],"see":[297,300],"text]":[298,301]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-03-03T00:00:00"}